OptimizeRx Corp. (NASDAQ:OPRX) Given Average Rating of “Moderate Buy” by Analysts

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.4286.

A number of analysts recently issued reports on OPRX shares. Roth Mkm dropped their price objective on OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, March 6th. B. Riley Financial lowered their price target on OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings cut OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, May 14th. UBS Group set a $10.00 price target on OptimizeRx in a report on Wednesday, May 13th. Finally, Stephens lowered their price target on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 13th.

OptimizeRx Stock Performance

Shares of OPRX opened at $5.28 on Friday. The stock’s 50-day simple moving average is $5.87 and its 200 day simple moving average is $9.00. The stock has a market capitalization of $99.05 million, a price-to-earnings ratio of 15.09 and a beta of 1.13. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.37 and a current ratio of 5.37. OptimizeRx has a 52-week low of $4.57 and a 52-week high of $22.25.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $19.84 million for the quarter, compared to analysts’ expectations of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. Research analysts forecast that OptimizeRx will post 0.51 EPS for the current fiscal year.

OptimizeRx announced that its board has authorized a stock repurchase plan on Thursday, March 5th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Institutional Trading of OptimizeRx

Several institutional investors and hedge funds have recently modified their holdings of OPRX. CenterBook Partners LP purchased a new stake in shares of OptimizeRx in the 3rd quarter valued at about $6,331,000. Next Century Growth Investors LLC raised its holdings in shares of OptimizeRx by 139.8% in the 4th quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock valued at $6,196,000 after acquiring an additional 294,688 shares in the last quarter. Manatuck Hill Partners LLC raised its holdings in shares of OptimizeRx by 139.5% in the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock valued at $6,142,000 after acquiring an additional 265,000 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in shares of OptimizeRx by 42.8% in the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock valued at $13,836,000 after acquiring an additional 202,446 shares in the last quarter. Finally, Invesco Ltd. purchased a new position in shares of OptimizeRx during the 3rd quarter valued at about $4,081,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.